ACURX PHARMACEUTICALS INC

ACXPNASDAQ

🏆 #3806 by market capEarnings Aug 14US Equity

$1.47▼ $0.06 (−3.92%)

🌙 After hours$1.51▲ 2.72%Regular close · extended-hours price shown

1h—

24h▼ 3.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$6M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for ACXP.

Trading Snapshot

Day Range: $1.45 – $1.50
52-Week Range: $1.33 – $8.34
Volume: $2.42B
Avg Volume: $1.90B
Shares Outstanding: 4.3M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $509,758
Last Q Revenue: $127,283
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.46
Dividend Yield: —

Why Investors Own ACXP

✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
✓Healthy economics — 77% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$509,758▲ +18.3% YoY

Gross Margin (TTM)

76.7%▲ +3.9% YoY

Operating Income (TTM)

$180,964▲ +18.3% YoY

Free Cash Flow (TTM)

$111,637▲ +18.3% YoY

About ACURX PHARMACEUTICALS INC

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

🦦